You are here

  • Home
  • Archive
  • Volume 76, Issue 4
  • Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

Citation Tools

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Smolen JS, Kremer JM, Gaich CL, et al
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Annals of the Rheumatic Diseases 2017;76:694-700.